Regulatory Wins, Leadership Changes, and New Partnerships Creating Healthy Prospects - Research Report on Gilead, Biogen Idec, GlaxoSmithKline, Viropharma, and Celsion

NEW YORK, May 31, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Biogen Idec Inc. (NASDAQ: BIIB), GlaxoSmithKline plc. (ADR) (NYSE: GSK), Viropharma Inc. (NASDAQ: VPHM), and Celsion Corporation (NASDAQ: CLSN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Gilead Sciences, Inc. Research Report

On May 28, 2013, Gilead Sciences, Inc. (Gilead) announced that the European Commission has granted marketing authorization for Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil (as fumarate) 245 mg), a single tablet regimen for HIV-1 infection in adults who are antiretroviral treatment-naïve or infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild. Jürgen Rockstroh, MD, Professor of Medicine, University of Bonn, Germany and a Lead Investigator for one of the Stribild pivotal studies, commented, "Single tablet regimens make it easier for HIV patients to take their treatment consistently every day, which may improve their health outcomes. Stribild is a highly effective and well tolerated HIV treatment regimen, and is an important addition to the growing arsenal of simplified therapies in Europe." This approval allows the Company to market Stribild in all 27 countries of the European Union. Stribild is the third single tablet HIV regimen developed by the Company to become available in Europe, after Atripla and Eviplera. Stribild is also approved in the United States, Canada, Australia, South Korea, Japan, and Turkey. The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/9696_GILD]

Biogen Idec Inc. Research Report

On May 23, 2013, Biogen Idec Inc. (Biogen Idec) announced the appointment of Spyros Artavanis-Tsakonas, Ph.D., as the Company's Chief Scientific Officer (CSO). Dr. Artavanis-Tsakonas previously served as the Company's Chief Scientific Officer on an interim basis while on sabbatical from Harvard Medical School. He will now resume his role in a permanent capacity, and will also lead the Company's research strategy, capabilities, and discovery platforms. Doug Williams, Biogen Idec's Executive Vice President of Research and Development, said, "He will continue what he has successfully started at Biogen Idec-attracting and encouraging exceptional scientific talent, enhancing our existing early discovery programs, establishing extensive academic collaborations and leading our drug discovery strategy." The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/b35f_BIIB]

GlaxoSmithKline plc. (ADR) Research Report

On May 22, 2013, GlaxoSmithKline plc. (ADR) (GSK) and the Biomedical Advanced Research and Development Authority (BARDA), a segment of the U.S. Department of Health and Human Services (HHS), announced a first-of-its-kind collaboration that will support the development of several antibiotics to fight antibiotic resistance and bioterrorism. Under the terms of the agreement, HHS will provide $40 million for the initial 18-month agreement and up to $200 million if the agreement is renewed over five years. According to the GSK, this collaboration provides flexibility to move around GSK's antibacterial portfolio, rather than focusing on just one drug candidate and allow medicines to be studied for the potential treatment of both conventional and biothreat pathogens. The Full Research Report on GlaxoSmithKline plc. (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/2737_GSK]

Viropharma Inc. Research Report

On May 28, 2013, Viropharma, Inc. (Viropharma) announced results of data analyses from the randomized, placebo-controlled, and open label clinical trials of Cinryze (C1 esterase inhibitor [human]). The results showed the effectiveness of Cinryze in prevention of angioedema attacks in patients with Hereditary Angioedema (HAE). Dr. Zuraw, Professor of Medicine, Chief of Section of Allergy and Immunology, and Director of the Allergy and Immunology Training Program at the University of California, said, "While clinical trials have demonstrated the efficacy and safety of Cinryze for the long-term prevention of HAE, these data demonstrate that Cinryze is an important option, even in patients who have been managed on anabolic androgens and continue to experience multiple attacks of HAE." The Full Research Report on Viropharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/cf37_VPHM]

Celsion Corporation Research Report

On May 22, 2013, Celsion Corporation (Celsion) announced that its proprietary patent application, "Method of Storing Nanoparticle Formulations," has been granted in China, Japan, South Korea, and Taiwan, the four largest markets for liver cancer in the world. The Company holds an exclusive agreement with Duke University for its temperature sensitive liposome technology which covers the ThermoDox formulation. These newly issued patents pertain to methods of storing stabilized, temperature-sensitive liposomal formulations, and will assist in the protection of global rights by extending the overall term of the ThermoDox patent portfolio to August 2026. The Full Research Report on Celsion Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/ebef_CLSN]

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquires, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Source